{"authors": [["Wang", "Yang", "Y", "a School of Public Health, Southeast University , Nanjing , PR China."], ["Li", "Jingxin", "J", "b Jiangsu Provincial Center for Disease Control and Prevention , Nanjing , PR China."], ["Wang", "Yuxiao", "Y", "a School of Public Health, Southeast University , Nanjing , PR China."], ["Gu", "Wei", "W", "c School of Public Health, Nanjing Medical University , Nanjing , PR China."], ["Zhu", "Fengcai", "F", "b Jiangsu Provincial Center for Disease Control and Prevention , Nanjing , PR China."]], "date": "2017-12-20", "id": "29261406", "text": "Streptococcus pneumonia (S. pneumoniae) is responsible for significant morbidity and mortality throughout the world. The 23-valent pneumococcal polysaccharide vaccines (PPV23) have been widely used for many years, but challenges are remaining in some respects, especially for its effectiveness among high-risk populations and older adults. This review aims to summarize recent clinical trials and studies of PPV23 vaccination among healthy people \u2265 2\u00a0years of age and those with high-risk conditions such as pregnant women, individuals with immunocompromising diseases and other chronic conditions, and provide health officials in China and other developing countries a comprehensive understanding of the current vaccination strategies for PPV23 and for the combined use of PPV23 and pneumococcal conjugate vaccines (PCVs) in adults.", "doi": "10.1080/21645515.2017.1409316", "title": "Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations.", "journal": ["Human vaccines & immunotherapeutics", "Hum Vaccin Immunother"]}